A monkey sits still and, by thought alone, moves a cursor to a red dot on a screen — faster, its handlers say, than a human hand could. The chip in its skull has recorded single neurons for over two years. Now China wants to put that chip in people.
The system is BeiNao-2 (北脑二号), and it represents the riskier, higher-performance half of Beijing's two-track brain-computer interface (脑机接口) strategy.
What BeiNao-2 (北脑二号) is
- A 512-channel wireless fully-implantable engineering prototype.
- Fully invasive (侵入式): the electrode is implanted into brain tissue and records single neurons or tiny regions — far finer than the surface-level reading of extradural devices.
- Developed by NeuCyber (芯智达), spun out of the Beijing Institute for Brain Science and Brain-Inspired Research (北京脑科学与类脑研究所); the institute's director is Luo Minmin (罗敏敏).
- After long animal experiments, the plan is to launch a researcher-initiated trial (IIT) by the end of 2026.
The speed claim
The developers report a maximum information rate of about 7.2 bits per second (Beijing municipal and NCSTI sources; People's health channel cites 7.18 bit/s). They note this is close to the roughly 7.3 bits per second reported for Neuralink's comparable system — making BeiNao-2, on its own numbers, a rare Chinese invasive BCI that sits next to the U.S. leader on the metric that matters most: how fast intent becomes action.
In the primate demo, a monkey controlled a cursor "smoother than human manual operation." The electrode, described as thin as a hair, has recorded five to six hundred neurons at sub-millisecond resolution for more than two years without losing fidelity.
Why two "BeiNao" at once
Beijing runs both routes in parallel, which is unusual globally:
- BeiNao-1 (北脑一号) is semi-invasive (半侵入式), sitting extradurally — safer, faster to patients, now in confirmatory multicenter trials since March 2026, with registration expected around 2027.
- BeiNao-2 is fully invasive — higher risk, but the resolution to attempt finer motor and speech decoding.
The stated logic is pragmatic: ship the safer product to help patients now, while using the invasive one to push the performance boundary.
What it could restore
Because it reads single neurons, BeiNao-2 is aimed at finer decoding than extradural systems can manage — tighter motor control and, potentially, more natural speech or cursor work. A disclosed (not yet approved) registration plan attributed to institute advisors targets around 2030 for formal trials, with about 50 cases across 10 hospitals, including stroke hemiplegia, paraplegia, and ALS patients. We treat that as intent, not an approved protocol.
The bigger bet: performance versus safety
Every invasive BCI faces the same tradeoff. The deeper you implant, the cleaner the signal and the finer the control — but the greater the surgery and the longer the unknown about how tissue reacts over years. BeiNao-2 leans all the way into the high-performance end, while BeiNao-1 stays at the safer edge. That two-track design is the interesting part: it is not a hedge, it is a portfolio. If the extradural route reaches patients first and proves useful, the invasive route still gets to chase the harder decoding problems without holding patients hostage to its risk.
How the world is reading it
Western coverage tends to frame Chinese invasive BCI against Neuralink, and the 7.2-versus-7.3 bit/s figure invites exactly that comparison. But the more useful read is that several countries now have viable invasive programs, and the bottleneck is no longer "can we record neurons" — it is "can we do it safely in humans, for years, at scale, and prove it helps." On that metric, no one has won yet, and BeiNao-2 is still early.
Honest limitations
- BeiNao-2 is still pre-human — all confirmed results are from animal experiments; the end-2026 IIT is a plan, not a started trial.
- The 7.2 vs 7.3 bits/sec comparison is the developers' own; there is no independent head-to-head benchmark, and bit-rate alone does not capture clinical usefulness.
- The 2030 registration / 50-case plan is a disclosed intent, not an approved study design.
- "Fully invasive" carries higher surgical risk than extradural devices, and human long-term biocompatibility is unknown.
- All figures come from institute and affiliated-company disclosures reported by state media (NCSTI, Beijing government, People's Daily), not peer-reviewed publications.
What readers can do now
- If you follow clinical BCI, watch for the end-2026 IIT announcement from the Beijing Brain Institute / NeuCyber — that is the moment BeiNao-2 leaves the primate lab.
- If you compare BCI routes, weigh invasive (BeiNao-2, Neuralink) against extradural (BeiNao-1, NEO) on the risk-performance tradeoff; the higher bit-rate is real, the higher risk is real too.
- If you invest, the nearer-term catalyst is BeiNao-1's expected 2027 registration — BeiNao-2 is a 2026-trial, 2030-registration story, not a near-term product.